MENU
+Compare
RGNX
Stock ticker: NASDAQ
AS OF
Jun 2, 04:59 PM (EDT)
Price
$10.35
Change
+$1.50 (+16.95%)
Capitalization
443.92M

RGNX REGENXBIO Forecast, Technical & Fundamental Analysis

Regenxbio Inc is a biotechnology company... Show more

Industry: #Biotechnology
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for RGNX with price predictions
May 30, 2025

RGNX saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for RGNX moved out of overbought territory on May 27, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 62 similar instances where the indicator exited the overbought zone. In of the 62 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for RGNX moved out of overbought territory on May 05, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for RGNX turned negative on May 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 19, 2025. You may want to consider a long position or call options on RGNX as a result. In of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

RGNX moved above its 50-day moving average on May 09, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RGNX crossed bullishly above the 50-day moving average on April 25, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RGNX advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 146 cases where RGNX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.619) is normal, around the industry mean (16.282). P/E Ratio (0.000) is within average values for comparable stocks, (59.459). RGNX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (2.876) is also within normal values, averaging (270.467).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

RGNX is expected to report earnings to fall 881.58% to -93 cents per share on July 30

REGENXBIO RGNX Stock Earnings Reports
Q2'25
Est.
$-0.94
Q1'25
Missed
by $0.36
Q4'24
Beat
by $0.12
Q3'24
Missed
by $0.05
Q2'24
Beat
by $0.24
The last earnings report on May 12 showed earnings per share of 11 cents, missing the estimate of 47 cents. With 1.10M shares outstanding, the current market capitalization sits at 443.92M.
A.I. Advisor
published General Information

General Information

a developer of gene therapy treatments

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
9804 Medical Center Drive
Phone
+1 240 552-8181
Employees
344
Web
https://www.regenxbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WENCX37.020.36
+0.98%
Allspring Mid Cap Growth Fund - Cl C
BGLYX14.300.09
+0.63%
Brookfield Global Listed InfrastructureI
FNKIX17.31-0.02
-0.12%
Frank Value Instl
AMVGX15.72-0.04
-0.25%
American Century Mid Cap Value R5
AMKIX12.02-0.13
-1.07%
American Century Emerging Markets I

RGNX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with RCKT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-1.34%
RCKT - RGNX
59%
Loosely correlated
-4.20%
DNLI - RGNX
55%
Loosely correlated
-2.22%
ARWR - RGNX
54%
Loosely correlated
-4.46%
BEAM - RGNX
53%
Loosely correlated
-3.00%
XNCR - RGNX
51%
Loosely correlated
+3.43%
More